2023 World Conference on Lung Cancer (Posters)-EP13.02. Entrectinib Amazing Efficacy in a Case of Lung Atypical Carcinoid with NTRK Gene Fusion

EP13.02. Entrectinib Amazing Efficacy in a Case of Lung Atypical Carcinoid with NTRK Gene Fusion - PDF(Slides)

Pdf Summary

This case report discusses the efficacy of entrectinib, a selective inhibitor approved for NTRK gene fusion-positive solid tumors, in a patient with lung atypical carcinoid. The patient, a 56-year-old woman, was initially diagnosed with lung atypical carcinoid in July 2020. She underwent several rounds of chemotherapy and radiotherapy for bone and brain metastases. However, the tumor persisted and progressed despite multiple lines of therapy, including targeted therapy and immunotherapy.<br /><br />In February 2023, the patient underwent surgical excision of a subcutaneous mass in the right chest wall, which confirmed the presence of atypical carcinoid with ETV6-NTRK2 gene fusion as demonstrated by next-generation sequencing (NGS). Following this, the patient was started on entrectinib at a dose of 600 mg once daily. After just one month of treatment with entrectinib, the tumor markers returned to normal and both the left pleural tumor and the right chest wall subcutaneous mass completely disappeared.<br /><br />This case highlights the remarkable efficacy of entrectinib as the seventh line of therapy for a patient with lung atypical carcinoid and NTRK gene fusion. It demonstrates that entrectinib can achieve a complete response in this rare neuroendocrine tumor, even after failure of platinum-based chemotherapy, targeted therapy, and immunotherapy.<br /><br />In conclusion, this case report emphasizes the importance of identifying NTRK gene fusions in patients with lung atypical carcinoid and suggests that entrectinib may be a promising treatment option for this subset of patients. Further research is needed to validate these findings and explore the potential of entrectinib in other neuroendocrine tumors with NTRK fusion.

Asset Subtitle

Hui Shi

Meta Tag

Speaker Hui Shi

Topic SCLC & Neuroendocrine Tumors: Case Report

Keywords

entrectinib

NTRK gene fusion

solid tumors

lung atypical carcinoid

efficacy

chemotherapy

radiotherapy

targeted therapy

immunotherapy

next-generation sequencing